Life Sciences

  • May 29, 2026

    DOJ Final Rule On Medical Pot Comes Under New Challenge

    A Trump administration rule loosening federal restrictions on state-sanctioned medical marijuana has been hit with another legal challenge in D.C. Circuit Court, initiated Thursday by a coalition of interests alleging they will be adversely impacted by the policy shift.

  • May 29, 2026

    Taxation With Representation: Latham, White & Case, Vischer

    In this week's Taxation With Representation, Fertitta Entertainment acquires Caesars Entertainment, Eli Lilly and Co. buys three companies involved in vaccine development, and nuclear energy company Newcleo Ltd. says it plans to go public by merging with a special purpose acquisition company, NewHold Investment Corp. III.

  • May 29, 2026

    UnitedHealthcare Defrauded Mass. Of $100M, AG Says

    UnitedHealthcare's "growth at all costs strategy" led the insurer's Massachusetts subsidiary to overcharge the state by more than $100 million by exaggerating the medical conditions and needs of seniors, the state's attorney general said in a Friday lawsuit.

  • May 28, 2026

    Calif. AG Sues 23andMe Over Lapses In Genetic Data Security

    California moved Thursday to sue the genetic testing company formerly known as 23andMe over a 2023 data breach that exposed the personal information of nearly 7 million customers, arguing that the company failed to implement even the most basic security measures and misled consumers about the scope of its safeguards and severity of the breach.

  • May 28, 2026

    WHO 'Changed The Rule' To Find Talc-Cancer Link, Jury Told

    A Johns Hopkins epidemiologist told a California jury Thursday considering bellwether claims that Johnson & Johnson's talc products caused deadly ovarian cancer in three women that a World Health Organization agency's recent reclassification of talc as being probably carcinogenic only came about because it "changed the rule" over what evidence it considered.

  • May 28, 2026

    Trans Patients Say Stanford Can't Give DOJ Medical Records

    A group of transgender adolescents who received gender-related care at a Stanford Medicine hospital urged a California federal court to order the hospital not to turn over any of their medical records in response to a criminal subpoena issued by a grand jury in Texas.

  • May 28, 2026

    Injury Law Roundup: Freight Brokers, Uber Lose Key Cases

    The U.S. Supreme Court's green light of negligent hiring claims against freight brokers in highway crash cases and an adverse verdict against Uber in the sexual assault multidistrict litigation lead Law360's Injury Law Roundup.

  • May 28, 2026

    Hospital Operator, Execs Ink $32M FCA Settlement With Feds

    Psychiatric hospital operator Oglethorpe Inc. has agreed to pay $32 million and be excluded from all federal healthcare programs for 10 years to resolve allegations it knowingly failed to return Medicare overpayments in violation of the False Claims Act.

  • May 28, 2026

    McDermott-Led Ampersand Clinches $1.5B Fund

    Healthcare-focused private equity firm Ampersand Capital Partners, advised by McDermott Will & Schulte, on Thursday revealed that it closed its latest fund with $1.5 billion.

  • May 28, 2026

    3 Federal Circuit Clashes To Watch In June

    The Federal Circuit's argument calendar next month includes a dispute between Micron and Netlist over Idaho's law against "bad faith" patent suits, and appeals of multimillion-dollar verdicts against Boston Scientific on a stent patent and TP-Link on Wi-Fi patents.

  • May 28, 2026

    Zoetis Hit With Investor Suit Over Slowed Pet Drug Sales

    Animal health company Zoetis Inc. has been hit with a proposed shareholder class action accusing it of misleading investors about its growth prospects amid rising competition and shifting trends in the veterinary industry.

  • May 28, 2026

    J&J Unit Cleared In Blood Pump Patent Suit In Mass.

    A Massachusetts federal jury on Thursday cleared a Johnson & Johnson MedTech subsidiary of allegations that it infringed a blood pump patent owned by a unit of Swedish medical device company Getinge AB.

  • May 28, 2026

    Chancery Tosses Insider Financing Suit Against Ayala Brass

    The Delaware Chancery Court has dismissed a stockholder derivative suit against several venture capital investors and directors of biotechnology company Ayala Pharmaceuticals Inc., ruling that the plaintiff failed to show the board could not independently evaluate litigation over a disputed 2023 financing deal.

  • May 28, 2026

    Abbott Labs Settles Ill. Genetic Privacy Suit

    Abbott Laboratories has inked a settlement with a proposed class of workers alleging the company's onboarding materials asked for employees' medical history in violation of an Illinois law aimed at protecting residents' genetic information, prompting an Illinois federal judge to dismiss the case Thursday.

  • May 28, 2026

    Legislative Update: Cannabis And Psychedelics Bill Roundup

    Tennessee became the latest state to approve a policy paving the way for more research into ibogaine; Vermont lawmakers brought a bill doubling cannabis potency and possession limits closer to the finish line; and California legislators approved a bill banning the sale of "laughing gas" used for recreational purposes. Here are the major moves in cannabis and psychedelics legislation from the past week.

  • May 28, 2026

    Husch Blackwell Adds Manatt Healthcare Duo In LA

    Husch Blackwell LLP announced that a pair of Los Angeles-based commercial litigators from Manatt Phelps & Phillips LLP have joined the firm as part of its focus on expanding its California healthcare capabilities.

  • May 28, 2026

    Ex-Reebok CEO Says Biotech Investor Suit Was Shakedown

    Former Reebok CEO and billionaire philanthropist Paul Fireman said a "baseless" shareholder lawsuit against him and a biotech company he later sold to Janssen Pharmaceuticals Inc. for $85 million was an effort to get him to "cave" to demands for more money, according to a complaint filed in Massachusetts state court Wednesday.

  • May 28, 2026

    9th Circ. Won't Revisit FCA Ruling Over Drug Price Program

    The Ninth Circuit has said it will not disturb its March ruling allowing a hospital chain to pursue a False Claims Act lawsuit against various pharmaceutical companies for allegedly causing the government to overpay for drugs under a discount program.

  • May 28, 2026

    Split Fed. Circ. Says $452M Trade Secret Case Was Untimely

    A split Federal Circuit panel on Thursday erased Insulet Corp.'s trade secret victory against EOFlow Co. Ltd., holding that the medical device maker filed its claims too late and reversing a $452 million jury verdict that was later reduced to $59.4 million.

  • May 27, 2026

    Pharmacies Beat Fla. Hospitals' Opioids Suit

    A Florida state judge has handed Walmart, Walgreens and CVS a win in a fight with hospitals over treatment of opioid-addicted patients, finding the hospitals cannot recover damages under state racketeering law because their injuries are indirect.

  • May 27, 2026

    Inovio Brass Hit With Suit Over FDA Approval Claims

    Executives and directors of Inovio Pharmaceuticals Inc. on Wednesday were slapped with a shareholder derivative suit accusing them of damaging the company with misleading statements regarding the likelihood that the U.S. Food and Drug Administration would grant priority review to its DNA medicine.

  • May 27, 2026

    3 Generic Drug Antitrust Deals Totaling $17.9M Get Final Nod

    A Connecticut federal judge on Wednesday gave final approval to a $17.9 million generic drug price-fixing settlement between pharmaceutical companies Bausch Health US LLC, Bausch Health Americas Inc., and Lannett Co. Inc. and 48 states, territories, and governments, finding the terms reasonable despite an objection.

  • May 27, 2026

    ProPublica Denied Access To Ranbaxy Antitrust MDL Docs

    A Massachusetts federal court denied ProPublica's bid to unseal court filings in settled multidistrict litigation alleging a subsidiary of Indian drugmaker Sun Pharmaceuticals illegally delayed market entry of generic drugs, ruling the nonprofit news organization's request came too late in the case.

  • May 27, 2026

    Pharmacies Hit With Injunction In Gilead Counterfeit Drug Row

    A New York federal judge has issued a preliminary injunction blocking a pair of Queens pharmacies from selling any human immunodeficiency virus medications that bear the Gilead name or the name of two of its products.

  • May 27, 2026

    NJ Justices Revive Eye Injury Suit For 'Gatekeeping' Test

    The Supreme Court of New Jersey revived a woman's suit alleging she suffered serious eye injuries because of a defect in Allergan USA Inc.'s product Ozurdex, ruling Wednesday that the trial court failed to conduct the gatekeeping inquiry required when there is a dispute over the reliability of expert testimony.

Expert Analysis

  • How The Coming Months Will Shape State Drug Price Boards

    Author Photo

    The future of state prescription drug affordability boards may be determined in the next few months, between an upcoming court decision in a challenge against state authority to set drug prices, and pending state decisions about whether to use federal Medicare maximum fair prices as reference, say Michael Kolber, Steven Chen and Kelechi Ezealaji at Manatt.

  • High Court 'Skinny Label' Case Will Matter To Tech Litigators

    Author Photo

    Hikma v. Amarin, set for oral argument in the U.S. Supreme Court on Wednesday, has potential to affect not just generic drug label-based evidence in patent cases, but also how technology inducement cases are presented and proven, says attorney Abdul Abdullahi.

  • How Food, Beverage Claims May Preview Cosmetic Litigation

    Author Photo

    Class action litigation targeting cosmetics and personal care products is accelerating, with a playbook that comes from the food and beverage industry — and the defenses that succeeded, and failed, in past class actions offer a critical road map for beauty and personal care brands, say attorneys at Crowell.

  • Court's HRSA Policy Reversal Leaves 340B Rules Murky

    Author Photo

    A D.C. federal court's recent decision in Premier v. U.S. Department of Health limits the Health Resources and Services Administration's ability to enforce long-standing Section 340B interpretations through subregulatory guidance, leaving open core statutory questions about purchasing models, inventory classification and program oversight, says Martha Cramer at Hooper Lundy.

  • Series

    Officiating Football Makes Me A Better Lawyer

    Author Photo

    Though they may seem to have little in common, officiating football has sharpened many of the same skills that define effective lawyering in management-side labor and employment: preparation, judgment, composure, credibility and ability to make difficult decisions in real time, says Josh Nadreau at Fisher Phillips.

  • Fresenius Ruling May Shift Anti-Kickback Enforcement

    Author Photo

    The Ninth Circuit's recent decision in Fresenius v. Bonta suggests that businesses have a First Amendment right to donate to certain charities, even if those donations are motivated by economic self-interest, potentially calling into question years of Anti-Kickback Statute proceedings against pharmaceutical manufacturers for making similar donations, says Jonah Knobler at Patterson Belknap.

  • Written Consent Ruling May Signal Change For Telemarketing

    Author Photo

    The Fifth Circuit's ruling in Bradford v. Sovereign Pest Control is a takedown of the Federal Communications Commission's prior express written consent regulation, and because Loper Bright empowers courts to disregard agency interpretations, Telephone Consumer Protection Act litigants now have an opportunity to challenge previously settled FCC regulations, orders and interpretations, say attorneys at Manatt.

  • Series

    Law School's Missed Lessons: How To Draft Pleadings

    Author Photo

    Most law school graduates step into their first jobs without ever having drafted a complaint, answer, motion or other type of pleading, but that gap can be closed by understanding the strategy embedded in every filing, writing with clarity and purpose, and seeking feedback at every step, says Eric Yakaitis at Haug Barron.

  • At The Fed. Circ., Means-Plus-Function Is Not Quite Dead

    Author Photo

    Recent Federal Circuit opinions confirm that means-plus-function claims continue to be drafted, issued, litigated and even infringed — but minding the restrictions imposed over the years by courts and statute requires three steps, says Jay Yates at Patterson & Sheridan.

  • E-Discovery Quarterly: Recent Rulings On ESI Control

    Author Photo

    Several recent federal court decisions have perpetuated a split over what constitutes “control” of electronically stored information — with judges divided on whether the standard should turn on a party's legal right or practical ability to obtain the information, say attorneys at Sidley.

  • Opinion

    USPTO Should Let Inventors Valuate Patents In Prosecution

    Author Photo

    By building patent valuation into the application process, rather than waiting until potential litigation years down the line, the U.S. Patent and Trademark Office would streamline the process for inventors protecting and enforcing their patents, says John Powers at Powers IP.

  • 2 Discovery Rulings Break With Heppner On AI Privilege Issue

    Author Photo

    While a New York federal court’s recent ruling in U.S. v. Heppner suggests that some litigants’ communications with AI tools are discoverable, two other recent federal court decisions demonstrate that such interactions generally qualify for work-product protection under the Federal Rules of Civil Procedure, says Joshua Dunn at Brown Rudnick.

  • Series

    Isshin-Ryu Karate Makes Me A Better Lawyer

    Author Photo

    My involvement in martial arts, specifically Isshin-ryu, which has principles rooted in the eight codes of karate, has been one of the most foundational in the development of my personality, and particularly my approach to challenges — including in my practice of law, says Kaitlyn Stone at Barnes & Thornburg.

  • Microplastics On Water Contaminant List Could Spur Claims

    Author Photo

    The U.S. Environmental Protection Agency's proposal to include microplastics in its draft sixth Contaminant Candidate List under the Safe Drinking Water Act could influence consumer fraud claims and enforcement by state attorneys general, as well as claims against manufacturers from entities facing regulatory compliance costs, says Arie Feltman-Frank at Jenner & Block.

  • USPTO's AI Search Pilot May Reshape Patent Filing Strategy

    Author Photo

    The U.S. Patent and Trademark Office's new artificial intelligence search pilot aims to introduce earlier visibility into the prior art landscape, potentially influencing patent filing considerations and shifting the role of counsel to an earlier stage of the prosecution process, say attorneys at Foley & Lardner.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.